New drug combo tested in High-Stakes fight against rare blood cancers
NCT ID NCT02512497
Summary
This study tested whether adding the drug romidepsin to a stem cell transplant could better control several aggressive types of T-cell blood cancers. Researchers gave romidepsin before and after the transplant to 23 patients to find the safest dose and see if it helped. The main goals were to check for serious side effects and see if patients' bodies successfully accepted the new stem cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.